Drug Profile
Research programme: kinase inhibitors - Bayer Schering Pharma
Latest Information Update: 21 Mar 2011
Price :
$50
*
At a glance
- Originator Nycomed
- Developer Bayer HealthCare Pharmaceuticals
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Mar 2011 No development reported - Preclinical for Cancer in Germany (unspecified route)
- 11 Aug 2008 Preclinical trials in Cancer in Germany (unspecified route)